{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:44:46Z","timestamp":1771461886236,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Primary prophylactic implantable cardioverter-defibrillators (ICDs) in patients with non-ischaemic cardiomyopathy (NICMP) remains controversial. This study sought to assess the benefit of ICD therapy with or without cardiac resynchronisation therapy (CRT) in patients with NICMP. In addition, data were compared with real-world clinical data to perform a\u00a0risk\/benefit analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Relevant randomised clinical trials (RCTs) published in meta-analyses since DANISH, and in PubMed, EMBASE and Cochrane databases from 2016 to 2020 were identified. The benefit of ICD therapy stratified by CRT use was assessed using random effects meta-analysis techniques.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Six RCTs were included in the meta-analysis. Among patients without CRT, ICD use was associated with a\u00a024% reduction in mortality (hazard ratio [HR]: 0.76; 95% confidence interval [CI]: 0.62\u20130.93; <jats:italic>P<\/jats:italic>\u202f=\u20090.008). In contrast, among patients with CRT, a\u00a0CRT-defibrillator was not associated with reduced mortality (HR: 0.74, 95% CI 0.47\u20131.16; <jats:italic>P<\/jats:italic>\u202f=\u20090.19). For ICD therapy without CRT, absolute risk reduction at 3\u2011years follow-up was 3.7% yielding a\u00a0number needed to treat of\u00a027.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>ICD use significantly improved survival among patients with NICMP who are not eligible for CRT. Considering CRT, the addition of defibrillator therapy was not significantly associated with mortality benefit compared with CRT pacemaker.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12471-022-01718-3","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T12:03:34Z","timestamp":1662465814000},"page":"89-99","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Implantable defibrillator therapy and mortality in patients with non-ischaemic dilated cardiomyopathy"],"prefix":"10.1007","volume":"31","author":[{"given":"D. A.","family":"Theuns","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. E.","family":"Verstraelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. C. J.","family":"van der Lingen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. P.","family":"Delnoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. P.","family":"Allaart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"van Erven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. H.","family":"Maass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Vernooy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. A. M.","family":"Wilde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. G.","family":"Meeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"1718_CR1","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/j.hrthm.2017.10.036","volume":"15","author":"SM Al-Khatib","year":"2018","unstructured":"Al-Khatib\u00a0SM, Stevenson\u00a0WG, Ackerman\u00a0MJ, et al. 2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Heart Rhythm. 2018;15:e73\u2013e189.","journal-title":"Heart Rhythm"},{"key":"1718_CR2","first-page":"1601","volume":"17","author":"SG Priori","year":"2015","unstructured":"Priori\u00a0SG, Blomstrom-Lundqvist\u00a0C, Mazzanti\u00a0A, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace. 2015;17:1601\u201387.","journal-title":"Europace"},{"key":"1718_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa043399","volume":"352","author":"GH Bardy","year":"2005","unstructured":"Bardy\u00a0GH, Lee\u00a0KL, Mark\u00a0DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N\u00a0Engl J Med. 2005;352:225\u201337.","journal-title":"N Engl J Med"},{"key":"1718_CR4","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa013474","volume":"346","author":"AJ Moss","year":"2002","unstructured":"Moss\u00a0AJ, Zareba\u00a0W, Hall\u00a0WJ, et\u00a0al. Prophylactic implantation of a\u00a0defibrillator in patients with myocardial infarction and reduced ejection fraction. N\u00a0Engl J Med. 2002;346:877\u201383.","journal-title":"N Engl J Med"},{"key":"1718_CR5","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1001\/jama.292.23.2874","volume":"292","author":"AS Desai","year":"2004","unstructured":"Desai\u00a0AS, Fang\u00a0JC, Maisel\u00a0WH, Baughman\u00a0KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a\u00a0meta-analysis of randomized controlled trials. JAMA. 2004;292:2874\u20139.","journal-title":"JAMA"},{"key":"1718_CR6","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","volume":"375","author":"L Kober","year":"2016","unstructured":"Kober\u00a0L, Thune\u00a0JJ, Nielsen\u00a0JC, et\u00a0al. Defibrillator implantation in patients with nonischemic systolic heart failure. N\u00a0Engl J Med. 2016;375:1221\u201330.","journal-title":"N Engl J Med"},{"issue":"3","key":"1718_CR7","doi-asserted-by":"publisher","first-page":"e12253","DOI":"10.1111\/1755-5922.12253","volume":"35","author":"T Akel","year":"2017","unstructured":"Akel\u00a0T, Lafferty\u00a0J. Implantable cardioverter defibrillators for primary prevention in patients with nonischemic cardiomyopathy. Cardiovasc Ther. 2017;35:e12253.","journal-title":"Cardiovasc Ther"},{"key":"1718_CR8","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1001\/jamacardio.2017.0630","volume":"2","author":"SM Al-Khatib","year":"2017","unstructured":"Al-Khatib\u00a0SM, Fonarow\u00a0GC, Joglar\u00a0JA, et al. Primary prevention implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy. JAMA Cardiol. 2017;2:685\u20138.","journal-title":"JAMA Cardiol"},{"key":"1718_CR9","doi-asserted-by":"publisher","first-page":"e016352","DOI":"10.1136\/bmjopen-2017-016352","volume":"7","author":"AF Barakat","year":"2017","unstructured":"Barakat\u00a0AF, Saad\u00a0M, Elgendy\u00a0AY, et al. Primary prevention implantable cardioverter defibrillator in patients with non-ischaemic cardiomyopathy. BMJ Open. 2017;7:e16352.","journal-title":"BMJ Open"},{"key":"1718_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/0003319717710851","volume":"69","author":"R Cavalcanti","year":"2018","unstructured":"Cavalcanti\u00a0R, Aboul-Hosn\u00a0N, Morales\u00a0G, Abdel-Latif\u00a0A. Implantable cardioverter defibrillator for the primary prevention of sudden cardiac death in patients with nonischemic cardiomyopathy. Angiology. 2018;69:297\u2013302.","journal-title":"Angiology"},{"key":"1718_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1161\/CIRCULATIONAHA.116.026056","volume":"135","author":"H Golwala","year":"2017","unstructured":"Golwala\u00a0H, Bajaj\u00a0NS, Arora\u00a0G, Arora\u00a0P. Implantable cardioverter-defibrillator for nonischemic cardiomyopathy. Circulation. 2017;135:201\u20133.","journal-title":"Circulation"},{"key":"1718_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/joa3.12017","volume":"34","author":"SU Khan","year":"2018","unstructured":"Khan\u00a0SU, Ghimire\u00a0S, Talluri\u00a0S, et al. Implantable cardioverter defibrillator in nonischemic cardiomyopathy. J\u00a0Arrhythm. 2018;34:4\u201310.","journal-title":"J Arrhythm"},{"key":"1718_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.7326\/M17-0120","volume":"167","author":"M Kolodziejczak","year":"2017","unstructured":"Kolodziejczak\u00a0M, Andreotti\u00a0F, Kowalewski\u00a0M, et al. Implantable cardioverter-defibrillators for primary prevention in patients with ischemic or nonischemic cardiomyopathy. Ann Intern Med. 2017;167:103\u201311.","journal-title":"Ann Intern Med"},{"key":"1718_CR14","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/jce.13192","volume":"28","author":"FK Luni","year":"2017","unstructured":"Luni\u00a0FK, Singh\u00a0H, Khan\u00a0AR, et al. Mortality effect of ICD in primary prevention of nonischemic cardiomyopathy. J\u00a0Cardiovasc Electrophysiol. 2017;28:538\u201343.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1718_CR15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.21037\/cdt.2017.06.06","volume":"7","author":"A Masri","year":"2017","unstructured":"Masri\u00a0A, Hammadah\u00a0M, Adelstein\u00a0E, Jain\u00a0S, Saba\u00a0S. Implantable cardioverter defibrillator in non-ischemic cardiomyopathy. Cardiovasc Diagn Ther. 2017;7:397\u2013404.","journal-title":"Cardiovasc Diagn Ther"},{"key":"1718_CR16","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.jacep.2017.02.006","volume":"3","author":"M Anantha Narayanan","year":"2017","unstructured":"Anantha Narayanan\u00a0M, Vakil\u00a0K, Reddy\u00a0YN, et al. Efficacy of implantable cardioverter-defibrillator therapy in patients with nonischemic cardiomyopathy. JACC Clin Electrophysiol. 2017;3:962\u201370.","journal-title":"JACC Clin Electrophysiol"},{"key":"1718_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10840-017-0260-8","volume":"49","author":"J Romero","year":"2017","unstructured":"Romero\u00a0J, Chaudhary\u00a0R, Garg\u00a0J, et al. Role of implantable cardioverter defibrillator in non-ischemic cardiomyopathy. J\u00a0Interv Card Electrophysiol. 2017;49:263\u201370.","journal-title":"J Interv Card Electrophysiol"},{"key":"1718_CR18","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1093\/eurheartj\/ehx028","volume":"38","author":"MJ Shun-Shin","year":"2017","unstructured":"Shun-Shin\u00a0MJ, Zheng\u00a0SL, Cole\u00a0GD, et al. Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease. Eur Heart\u00a0J. 2017;38:1738\u201346.","journal-title":"Eur Heart J"},{"key":"1718_CR19","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/jce.13204","volume":"28","author":"S Stavrakis","year":"2017","unstructured":"Stavrakis\u00a0S, Asad\u00a0Z, Reynolds\u00a0D. Implantable cardioverter defibrillators for primary prevention of mortality in patients with nonischemic cardiomyopathy. J\u00a0Cardiovasc Electrophysiol. 2017;28:659\u201365.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1718_CR20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00392-017-1079-0","volume":"106","author":"G Wolff","year":"2017","unstructured":"Wolff\u00a0G, Lin\u00a0Y, Karathanos\u00a0A, et al. Implantable cardioverter\/defibrillators for primary prevention in dilated cardiomyopathy post-DANISH. Clin Res Cardiol. 2017;106:501\u201313.","journal-title":"Clin Res Cardiol"},{"key":"1718_CR21","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1136\/heartjnl-2017-311430","volume":"104","author":"AC Alba","year":"2018","unstructured":"Alba\u00a0AC, Foroutan\u00a0F, Duero Posada\u00a0J, et al. Implantable cardiac defibrillator and mortality in non-ischaemic cardiomyopathy: an updated meta-analysis. Heart. 2018;104:230\u20136.","journal-title":"Heart"},{"key":"1718_CR22","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1136\/heartjnl-2016-310850","volume":"104","author":"SAS Beggs","year":"2018","unstructured":"Beggs\u00a0SAS, Jhund\u00a0PS, Jackson\u00a0CE, et al. Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a\u00a0review and meta-analysis. Heart. 2018;104:144\u201350.","journal-title":"Heart"},{"key":"1718_CR23","doi-asserted-by":"publisher","first-page":"f211","DOI":"10.1093\/europace\/eux324","volume":"20","author":"J Romero","year":"2018","unstructured":"Romero\u00a0J, Diaz\u00a0JC, Grushko\u00a0M, et al. Clinical impact of implantable cardioverter-defibrillator in primary prevention of total mortality in non-ischaemic cardiomyopathy. 2018;20:f211\u2013f6.","journal-title":"Europace"},{"key":"1718_CR24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10741-018-9671-6","volume":"23","author":"WJ Siddiqui","year":"2018","unstructured":"Siddiqui\u00a0WJ, Aggarwal\u00a0S, Rafique\u00a0M, et al. Prophylactic use of the implantable cardioverter-defibrillator and its effect on the long-term survival, cardiovascular and sudden cardiac death in nonischemic cardiomyopathy patients\u2014a systematic review and meta-analysis. Heart Fail Rev. 2018;23:181\u201390.","journal-title":"Heart Fail Rev"},{"key":"1718_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian\u00a0R, Laird\u00a0N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"1718_CR26","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/europace\/euab012","volume":"23","author":"TE Verstraelen","year":"2021","unstructured":"Verstraelen\u00a0TE, van Barreveld\u00a0M, van Dessel\u00a0PHFM, et al. Development and external validation of prediction models to predict implantable cardioverter-defibrillator efficacy in primary prevention of sudden cardiac death. Europace. 2021;23:887\u201397.","journal-title":"Europace"},{"key":"1718_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/tri.12436","volume":"28","author":"T Pezawas","year":"2015","unstructured":"Pezawas\u00a0T, Grimm\u00a0M, Ristl\u00a0R, et al. Primary preventive cardioverter-defibrillator implantation (Pro-ICD) in patients awaiting heart transplantation. Transpl Int. 2015;28:34\u201341.","journal-title":"Transpl Int"},{"key":"1718_CR28","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1093\/eurheartj\/ehaa226","volume":"41","author":"M Zabel","year":"2020","unstructured":"Zabel\u00a0M, Willems\u00a0R, Lubinski\u00a0A, et al. Clinical effectiveness of primary prevention implantable cardioverter-defibrillators. Eur Heart\u00a0J. 2020;41:3437\u201347.","journal-title":"Eur Heart J"},{"key":"1718_CR29","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1161\/CIRCULATIONAHA.119.043012","volume":"140","author":"B Schrage","year":"2019","unstructured":"Schrage\u00a0B, Uijl\u00a0A, Benson\u00a0L, et al. Association between use of primary-prevention implantable cardioverter-defibrillators and mortality in patients with heart failure. Circulation. 2019;140:1530\u20139.","journal-title":"Circulation"},{"key":"1718_CR30","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1161\/01.CIR.0000012350.99718.AD","volume":"105","author":"D Bansch","year":"2002","unstructured":"Bansch\u00a0D, Antz\u00a0M, Boczor\u00a0S, et\u00a0al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 2002;105:1453\u20138.","journal-title":"Circulation"},{"key":"1718_CR31","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/S0735-1097(03)00297-3","volume":"41","author":"SA Strickberger","year":"2003","unstructured":"Strickberger\u00a0SA, Hummel\u00a0JD, Bartlett\u00a0TG, et al. Amiodarone versus implantable cardioverter-defibrillator. J\u00a0Am Coll Cardiol. 2003;41:1707\u201312.","journal-title":"J Am Coll Cardiol"},{"key":"1718_CR32","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa033088","volume":"350","author":"A Kadish","year":"2004","unstructured":"Kadish\u00a0A, Dyer\u00a0A, Daubert\u00a0JP, et\u00a0al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N\u00a0Engl J Med. 2004;350:2151\u20138.","journal-title":"N Engl J Med"},{"key":"1718_CR33","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa032423","volume":"350","author":"MR Bristow","year":"2004","unstructured":"Bristow\u00a0MR, Saxon\u00a0LA, Boehmer\u00a0J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N\u00a0Engl J Med. 2004;350:2140\u201350.","journal-title":"N Engl J Med"},{"key":"1718_CR34","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1093\/europace\/euq329","volume":"12","author":"DA Theuns","year":"2010","unstructured":"Theuns\u00a0DA, Smith\u00a0T, Hunink\u00a0MG, Bardy\u00a0GH, Jordaens\u00a0L. Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease. Europace. 2010;12:1564\u201370.","journal-title":"Europace"},{"key":"1718_CR35","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jchf.2021.02.013","volume":"9","author":"B Doran","year":"2021","unstructured":"Doran\u00a0B, Mei\u00a0C, Varosy\u00a0PD, et\u00a0al. The addition of a\u00a0defibrillator to resynchronization therapy decreases mortality in patients with nonischemic cardiomyopathy. JACC Heart Fail. 2021;9:439\u201349.","journal-title":"JACC Heart Fail"},{"key":"1718_CR36","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray\u00a0JJ, Packer\u00a0M, Desai\u00a0AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N\u00a0Engl J Med. 2014;371:993\u20131004.","journal-title":"N Engl J Med"},{"key":"1718_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad\u00a0F, McMurray\u00a0JJ, Krum\u00a0H, et\u00a0al. Eplerenone in patients with systolic heart failure and mild symptoms. N\u00a0Engl J Med. 2011;364:11\u201321.","journal-title":"N Engl J Med"},{"issue":"11","key":"1718_CR38","doi-asserted-by":"publisher","first-page":"e002539","DOI":"10.1161\/JAHA.115.002539","volume":"4","author":"S Barra","year":"2015","unstructured":"Barra\u00a0S, Providencia\u00a0R, Tang\u00a0A, et al. Importance of implantable cardioverter-defibrillator back-up in cardiac resynchronization therapy recipients. J\u00a0Am Heart Assoc. 2015;4:e2539.","journal-title":"J Am Heart Assoc"},{"key":"1718_CR39","doi-asserted-by":"publisher","first-page":"e008991","DOI":"10.1161\/CIRCEP.120.008991","volume":"14","author":"D Patel","year":"2021","unstructured":"Patel\u00a0D, Kumar\u00a0A, Black-Maier\u00a0E, et al. Cardiac resynchronization therapy with or without defibrillation in patients with nonischemic cardiomyopathy. Circ Arrhythm Electrophysiol. 2021;14:e8991.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"1718_CR40","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/europace\/euq328","volume":"13","author":"DA Theuns","year":"2011","unstructured":"Theuns\u00a0DA, Schaer\u00a0BA, Soliman\u00a0OI, et\u00a0al. The prognosis of implantable defibrillator patients treated with cardiac resynchronization therapy. Europace. 2011;13:62\u20139.","journal-title":"Europace"},{"key":"1718_CR41","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/ejhf.509","volume":"18","author":"G Boriani","year":"2016","unstructured":"Boriani\u00a0G, Berti\u00a0E, Belotti\u00a0LM, et al. Cardiac device therapy in patients with left ventricular dysfunction and heart failure. Eur J Heart Fail. 2016;18:693\u2013702.","journal-title":"Eur J Heart Fail"},{"key":"1718_CR42","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/ejhf.685","volume":"19","author":"AC Ruwald","year":"2017","unstructured":"Ruwald\u00a0AC, Vinther\u00a0M, Gislason\u00a0GH, et al. The impact of co-morbidity burden on appropriate implantable cardioverter defibrillator therapy and all-cause mortality. Eur J Heart Fail. 2017;19:377\u201386.","journal-title":"Eur J Heart Fail"},{"key":"1718_CR43","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jchf.2014.06.007","volume":"2","author":"BA Steinberg","year":"2014","unstructured":"Steinberg\u00a0BA, Al-Khatib\u00a0SM, Edwards\u00a0R, et al. Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities. JACC Heart Fail. 2014;2:623\u20139.","journal-title":"JACC Heart Fail"},{"key":"1718_CR44","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1093\/eurheartj\/ehv455","volume":"36","author":"E Marijon","year":"2015","unstructured":"Marijon\u00a0E, Leclercq\u00a0C, Narayanan\u00a0K, et al. Causes-of-death analysis of patients with cardiac resynchronization therapy. Eur Heart\u00a0J. 2015;36:2767\u201376.","journal-title":"Eur Heart J"},{"key":"1718_CR45","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1161\/CIRCULATIONAHA.117.028829","volume":"136","author":"MB Elming","year":"2017","unstructured":"Elming\u00a0MB, Nielsen\u00a0JC, Haarbo\u00a0J, et al. Age and outcomes of primary prevention implantable cardioverter-defibrillators in patients with nonischemic systolic heart failure. Circulation. 2017;136:1772\u201380.","journal-title":"Circulation"},{"key":"1718_CR46","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ahj.2019.12.017","volume":"222","author":"KC Bilchick","year":"2020","unstructured":"Bilchick\u00a0KC, Wang\u00a0Y, Curtis\u00a0JP, et\u00a0al. Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients. Am Heart\u00a0J. 2020;222:93\u2013104.","journal-title":"Am Heart J"},{"key":"1718_CR47","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ijcard.2021.01.011","volume":"330","author":"DAMJ Theuns","year":"2021","unstructured":"Theuns\u00a0DAMJ, Schaer\u00a0BA, Caliskan\u00a0K, et al. Application of the heart failure meta-score to predict prognosis in patients with cardiac resynchronization defibrillators. Int J Cardiol. 2021;330:73\u20139.","journal-title":"Int J Cardiol"},{"key":"1718_CR48","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1093\/eurheartj\/ehz103","volume":"40","author":"J Cadrin-Tourigny","year":"2019","unstructured":"Cadrin-Tourigny\u00a0J, Bosman\u00a0LP, Nozza\u00a0A, et al. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart\u00a0J. 2019;40:1850\u20138.","journal-title":"Eur Heart J"},{"key":"1718_CR49","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/eurheartj\/eht439","volume":"35","author":"C O\u2019Mahony","year":"2014","unstructured":"O\u2019Mahony\u00a0C, Jichi\u00a0F, Pavlou\u00a0M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy. Eur Heart\u00a0J. 2014;35:2010\u201320.","journal-title":"Eur Heart J"},{"key":"1718_CR50","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1093\/eurheartj\/ehab294","volume":"42","author":"TE Verstraelen","year":"2021","unstructured":"Verstraelen\u00a0TE, van Lint\u00a0FHM, Bosman\u00a0LP, et al. Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers-reaching the frontiers of individual risk prediction. Eur Heart\u00a0J. 2021;42:2842\u201350.","journal-title":"Eur Heart J"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-022-01718-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-022-01718-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-022-01718-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T14:24:09Z","timestamp":1677162249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-022-01718-3"}},"subtitle":["An\u00a0updated meta-analysis and effect on Dutch clinical practice by the Task Force of the Dutch Society of Cardiology"],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1718"],"URL":"https:\/\/doi.org\/10.1007\/s12471-022-01718-3","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"assertion":[{"value":"28 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.A.\u00a0Theuns has received research grants from Biotronik and Boston Scientific, and consulting fees from Boston Scientific. P.P.\u00a0Delnoy has received speaker and consulting fees from Abbott, Biotronik, Boston Scientific, Microport and Medtronic. C.P.\u00a0Allaart has received institutional research grants from Abbott, Biotronik and Medtronic, and received speaker fees from Abbott and Biotronik. K.\u00a0Vernooy is listed as consultant for Abbott, Medtronic and received speaker fees from Abbott, Medtronic and Microport. T.E.\u00a0Verstraelen, A.C.J.\u00a0van der Lingen, L.\u00a0van Erven, A.H.\u00a0Maass, A.A.M.\u00a0Wilde, E.\u00a0Boersma and J.G.\u00a0Meeder declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}